Navigation Links
Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Date:8/19/2007

Multi-Center International Study to Determine the Efficacy of LBH589 in

Patients with Relapsed or Refractory Multiple Myeloma

NORWALK, Conn., Aug. 14 /PRNewswire-USNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) today announced its participation in a Phase II study to determine the efficacy of LBH589 for the treatment of patients with relapsed or refractory multiple myeloma. LBH589 is an orally administered deacetylase inhibitor developed by Novartis Pharmaceuticals.

The MMRC is the only research model of its kind bringing together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell. In addition to its most recent partnership with Novartis, the MMRC is facilitating several other clinical trials, including a Phase I study of NPI- 0052, a proteasome inhibitor, in collaboration with Nereus Pharmaceuticals, and a Phase I study of perifosine, lenalidomide (REVLIMID(R)), and dexamethasone in collaboration with Keryx Biopharmaceuticals.

"Deacetylase inhibitors may represent a new treatment options for cancer patients and the MMRC is proud to work with Novartis to advance this important clinical program," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC, as well as a myeloma patient. "This trial and the others the MMRC is facilitating demonstrate the importance of novel collaborations in bringing new treatments to patients."

Named ALPHA-MM, this trial is a single arm, open label, multi-center global study that will enroll 144 patients in the United States, Canada, and Europe. MMRC Member Institutions that will enroll patients are Dana-Farber Cancer Institute, City of Hope National Medical Center, Emory University, Hackensack University Medical Center, Mayo Clinic, H. Lee Moffitt Cancer Center & Research Institute, and Washington University.

This trial is open to patients with relapsed or r
'/>"/>

SOURCE The Multiple Myeloma Research Consortium

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Officer, will present at the Stem Cell Meeting on ... 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... , Sept. 30, 2014 STUDY OBJECTIVES ... study is to provide an overview of the ... for protein drugs/therapeutics. The key objective is to ... protein drugs as an important tool in the ... present and future strategies within the protein therapeutics ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3
(Date:10/1/2014)... A new research study published today in the ... in patients older than 50 years with moderate or ... benefit. , Researchers from the University of Melbourne randomly ... knee pain to no acupuncture or sham or pretend ... weeks with participants and acupuncturists blinded to laser and ...
(Date:10/1/2014)... with increased inflammation, including those receiving cytokines for ... depression. For example, a 6-month treatment course of ... causes depression in approximately 30% of patients. ... fish oil, have a long list of health ... and reducing triglyceride levels. These nutritional compounds are ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post explaining ... , Senior citizens can qualify for affordable term life ... who are over 50 years old. Some term life ... examination. , Term life insurance with a simplified issue ... Having life insurance during retirement is important for covering ...
(Date:10/1/2014)... 2014 Bedros Keuilian is not only ... fitness boot camps, he’s also considered the leading expert ... sold out business summits, a line of high-demand fitness ... a recent Spike TV reality show to his name. ... the time for personal trainers and fitness business owners ...
(Date:10/1/2014)... Oregon (PRWEB) October 01, 2014 Phoseon ... solutions , continues to expand the business worldwide. This ... along with additional capacity for manufacturing efforts. The company ... the last five years and expects this growth to ... LED curing technology gains worldwide adoption. , “We ...
Breaking Medicine News(10 mins):Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... A clinical trial in Cambodia has found it possible ... very weak immune systems and newly diagnosed tuberculosis (TB) ... treatment, rather than waiting eight weeks, as has been ... Institute of Allergy and Infectious Diseases (NIAID), part of ...
... July 22 Adult circumcision has been proposed as a ... study by the University of Pittsburgh Graduate School of ... suggests it would have a very small effect on reducing ... thought to reduce the risk of HIV transmission by removing ...
... insulin resistance and the action of diabetes drugs such ... improved medications that are more selective and safer, say ... Institute. "Our findings strongly suggest that good and ... designing second-generation drugs that focus on the newly uncovered ...
... College Park, MD (July 20, 2010) -- Eighty years ago, ... of metabolism, but the idea went out of vogue. Now, ... cancer and other common diseases. Metabolism is a highly connected ... pathways. Such parallelism can mask how genes are linked ...
... Cancer surgery wreaks havoc on a body,s immune system and ... of those who undergo surgery for tumor removal experience a ... of the body. A new clinical approach being ... the key to making cancer operations more successful. Prof. Shamgar ...
... group of patients at one of the nation,s largest ... who have previously refused colorectal cancer screening, are willing ... but not willing to pay for the exam themselves ... in the August issue of the American Journal ...
Cached Medicine News:Health News:NIH-funded study finds early HAART during TB treatment boosts survival rate in co-infected people 2Health News:Scientists find unsuspected molecular link between obesity and insulin resistance 2Health News:Scientists find unsuspected molecular link between obesity and insulin resistance 3Health News:A new drug treatment to close the window on colon cancer 2Health News:Lack of insurance coverage remains obstacle to wider colorectal cancer screening with CT colonography 2
... Provides an approach to treatment ... a pressure range to 25 ... to treat patients with severe ... features integrated humidification and built-in ...
... specifically designed for monitoring the performance ... for separation and quantification of cholesterol ... in patient serum samples. Liposure is ... and A (IDL), LDL subfractions, HDL ...
This control is intended for monitoring cell counts in patient cerebrospinal fluid samples, performed manually using a hemocytometer. Spinalscopics is fortified to target levels with purified chemica...
... Ammonia/Alcohol Control is intended ... various ammonia and ethanol assay ... is targeted at clinically significant ... Assay values are provided for ...
Medicine Products: